Skip to main content

BioGeneration Ventures — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

47
Companies
$2.2B
Total invested
$58.5M
Avg. check
12
Industries
Biotechnology 18Health Care 14Therapeutics 11Medical 9Pharmaceutical 6Biopharma 3+6 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2547 of 47
TargED Biopharmaceuticals
December 2025

TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.

Biopharma · Utrecht$25.3M Series A
Confo Therapeutics
October 2025

Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need.

Biotechnology · Brussels$1.2M Grant
Azafaros
May 2025

Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.

Biotechnology · Leiden$147.6M Series B
Phosphoenix
April 2025

Phosphoenix is a neurotechnology company.

Health Care · Delft$342K Debt Financing
Avidicure
April 2025

Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.

Oegstgeest$50.0M Seed
Rhygaze
January 2025

Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.

Biotechnology · Basel$86.0M Series A
Tiga TX
December 2024

Tiga TX develops an IgA therapeutic monoclonal antibody platform for the treatment of solid tumors.

Biotechnology · Boston$35.5M Grant
Kivu Bioscience
October 2024

Kivu Bioscience is a biotechnology company that focuses on developing next-generation antibody-drug conjugates to target cancer.

Biotechnology · San Francisco$92.0M Series A
Tanai Therapeutics
September 2024

Therapeutics for obesity and obesity-related conditions.

Health Care · Gent$3.5M Seed
Brenig Therapeutics
July 2024

Brenig Therapeutics develops therapies for neurodegenerative disorders.

Health Care · Dover$65.0M Series A
CatalYm
July 2024

CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.

Biotechnology · Planegg$150.0M Series D
FundaMental Pharma
April 2024

FundaMental Pharma is a neuroscience company with a portfolio at the preclinical stage.

Health Care · Heidelberg$2.9M Seed
Artica Therapeutics
November 2023

Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food.

Biotechnology · Leiden$12.7M Seed
Tessellate BIO
October 2023

Tessellate BIO is a biotechnology business in the preclinical stage that focuses on advanced Synthetic Lethality techniques.

Biotechnology · Naarden$8.5M Seed
Dualyx
May 2023

Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.

Biotechnology · Ghent$43.5M Series A
Complement Therapeutics
April 2023

Complement Therapeutics operates as a preclinical stage company.

Biotechnology · London$78.7M Series A
Scenic Biotech
March 2022

Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors.

Biometrics · Amsterdam$31.0M Series A
Dunad Therapeutics
November 2021

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.

Biotechnology · London$24.0M Series A
Fibrocor Therapeutics
January 2020

Fibrocor Therapeutics focuses on developing disease modifying therapeutics in fibrosis.

Biopharma · TorontoSeries Unknown
Escalier Biosciences
March 2018

Escalier Biosciences BV is a privately held biopharmaceutical company.

Biopharma · Encinitas$19.0M Series B
Cristal Therapeutics
November 2017

Cristal Therapeutics is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies.

Biotechnology · Maastricht$3.0M Grant
Lanthio Pharma
May 2014

Lanthio Pharma is focused on the research and development of therapeutic lantipeptide drugs for serious diseases.

Biotechnology · Groningen$4.9M Debt Financing
Dezima Pharma
February 2013

Dezima Pharma develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia.

Biotechnology · Naarden$18.6M Series Unknown

Where BioGeneration Ventures invests

Biotechnology18
Health Care14
Therapeutics11
Medical9
Pharmaceutical6
Biopharma3

About BioGeneration Ventures's portfolio

How many companies has BioGeneration Ventures invested in?

BioGeneration Ventures has invested in 47 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does BioGeneration Ventures invest in?

BioGeneration Ventures's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 12 different industry categories.

What is BioGeneration Ventures's largest investment?

Among tracked funding rounds, CatalYm received $150.0M in a Series D round. BioGeneration Ventures's total known invested capital is $2.2B.

What is the average investment size for BioGeneration Ventures?

BioGeneration Ventures's average investment size is $58.5M across its portfolio of 47 companies.

What are BioGeneration Ventures's most recent investments?

Recent BioGeneration Ventures portfolio additions include TargED Biopharmaceuticals, Confo Therapeutics, Azafaros, Phosphoenix, Avidicure. These companies were founded in 2020 or later.

Reach the founders behind these 47 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →